Zoonoses

Global WholeHealth Partners Corp (OTC:GWHP) Ships Its First Shipment of Over 20,000 Tests to Salud Previa of Tijuana, MX; Salud Previa Has Indicated That It Plans on Purchasing More Than 500,000 Tests Over the Next 12 Months

Retrieved on: 
Thursday, July 8, 2021
Medical specialties, Medicine, Health, Zoonoses, Glycoproteins, Medical tests, Pandemics, Virus, Immunoglobulin G, Antibody, Severe acute respiratory syndrome coronavirus 2, COVID-19

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • Global understands the need to be ahead of the virus to conquer the virus.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Inventive Health: COVID-19 Detected in 20 Seconds by Ultra-rapid Mouthwash or Nasal Swab Test Using Spectral Analysis Under MHRA Approval

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Health sciences, Sarbecovirus, COVID-19, Occupational safety and health, Public health, Zoonoses, Nasopharyngeal swab, Mouthwash, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Swab

These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.

Key Points: 
  • These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.
  • Samples can be collected using either a nasopharyngeal swab or non-invasive mouthwash solution.
  • The MHRA approval process is being driven by Inventive Health and is currently focused on the nasopharyngeal swab with the mouthwash alternative following soon.
  • All pathogens such as SARS-CoV-2 have a unique high resolution digital signature that can be detected using spectral analysis.

Pharmed and MyBio Partner to Bring First European Produced and Certified Covid-19 Rapid Antigen Self-test to Pharmacies Across Ireland

Retrieved on: 
Thursday, July 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical devices, Infectious diseases, Medicine, Medical tests, Clinical medicine, Health sciences, COVID-19, Occupational safety and health, Public health, Zoonoses, Medical terminology

The MP Biomedicals Covid-19 Rapid Antigen self-test is the only European manufactured, EU Certified Rapid Antigen Self-test, giving results in 15 mins and is 98.72% accurate.

Key Points: 
  • The MP Biomedicals Covid-19 Rapid Antigen self-test is the only European manufactured, EU Certified Rapid Antigen Self-test, giving results in 15 mins and is 98.72% accurate.
  • Peadar Coyle, Business Development Director at Pharmed Ltd said: With an almost 100% distribution network to pharmacies in Ireland we are delighted to be MyBios official distribution partner in Ireland.
  • These Rapid Antigen Self-Tests are an accurate, CE Certified, easy-to-use way to test for Covid-19 and are available in pharmacies nationwide.
  • Their Rapid Sars CoV-2 Antigen Self-Test supplied by MyBio is CE-IVD certified and easy to use.

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Retrieved on: 
Wednesday, July 7, 2021
Medical specialties, Health, Clinical medicine, Infectious causes of cancer, Healthcare-associated infections, Viral diseases, Epidemiology, Virus, Zoonoses, Hepatitis, Patent application, Viral hepatitis

11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.

Key Points: 
  • 11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.
  • The abstract contained in the Companys patent application describes the invention as follows: The compositions and methods are described for generating an immune response to a hepatitis B virus.
  • The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
  • We are pleased now to have been notified of the formal patent issuance.

ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement

Retrieved on: 
Wednesday, July 7, 2021
COVID-19, Occupational safety and health, Public health, Zoonoses, Articles, Health

WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced it has entered into a patent assignment agreement with the University Medical Center of Johannes Gutenberg University Mainz , Germany.

Key Points: 
  • WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced it has entered into a patent assignment agreement with the University Medical Center of Johannes Gutenberg University Mainz , Germany.
  • rNAPc2 is a recombinant protein therapeutic being developed by ARCA as a potential treatment for COVID-19 and other severe viral infections.
  • ASPEN-COVID-19 is an on-going Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.
  • ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.

Worldwide Respiratory Virus Infection Drugs Industry to 2030 - Players Include AstraZeneca, Sanofi and Cipla Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Infectious diseases, Pharmaceutical, Health, Epidemiology, Health sciences, Health, Articles, Zoonoses, Infectious diseases, Pandemics, Infection, Virus, Compound annual growth rate

The report provides revenue of the global respiratory virus infection drugs market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year.

Key Points: 
  • The report provides revenue of the global respiratory virus infection drugs market for the period 2018-2030, considering 2019 as the base year and 2030 as the forecast year.
  • The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.
  • Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.
  • Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.

Global Chloromethyl Isopropyl Carbonate (CMIC Value, Volume) Markets, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Chemicals, Plastics, Manufacturing, Pandemics, Health, Articles, Infectious diseases, Epidemiology, Virus, Zoonoses, HIV/AIDS

Chloromethyl Isopropyl Carbonate is one major chemical that is used commonly for making drugs to fight AIDS virus and other diseases like Hepatitis B.

Key Points: 
  • Chloromethyl Isopropyl Carbonate is one major chemical that is used commonly for making drugs to fight AIDS virus and other diseases like Hepatitis B.
  • The report presents the analysis of Chloromethyl Isopropyl Carbonate Market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • The report analyses Chloromethyl Isopropyl Carbonate Market By Application (Human Immunodeficiency Virus Intermediates, Hepatitis B Virus Intermediates and Others).
  • The Global Chloromethyl Isopropyl Carbonate has been analysed By Region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, United Kingdom, China and India).

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on: 
Thursday, July 1, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • A group of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 nasal swab testing from December 14, 2020, to April 10, 2021.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

Retrieved on: 
Wednesday, June 30, 2021
Health, Medical specialties, Articles, Epidemiology, Pandemics, Virus, Zoonoses, HIV, Tat

The findings were presented during the prestigious International Liver Conference, and presentations can be found ( Link to presentations .)

Key Points: 
  • The findings were presented during the prestigious International Liver Conference, and presentations can be found ( Link to presentations .)
  • Enochian BioSciences holds the exclusive license for the proprietary technology.
  • The daily measurements, studies of various doses of the product, and toxicity are important components for review by regulatory agencies.
  • A similar approach to potentially treat or cure HIV is being developed to expand Hijack RNA as an Enochian BioSciences platform to treat deadly viruses.

Prevalence of COVID-19 Among Hospitalized Infants Varies with Levels of Community Transmission

Retrieved on: 
Wednesday, June 30, 2021
COVID-19, Occupational safety and health, Public health, Zoonoses, Health, Articles, Pediatrics, Preterm birth, COVID-19 drug repurposing research

The study also found rates of COVID-19 positivity in this age group were lower when infection rates in the city were low.

Key Points: 
  • The study also found rates of COVID-19 positivity in this age group were lower when infection rates in the city were low.
  • However, cases of severe illness have been reported and some reports suggest young infants may be at higher risk for severe disease than older children.
  • Among 148 infants, 15 percent tested positive for COVID-19, and two of the 22 infants with COVID-19 required ICU admission, but were discharged safely.
  • The team also found a relatively low incidence (six percent) of infection of the hospitalized infants with other commonly occurring viruses, whether or not they had COVID-19.